Subscribe To
novartis eyes up to $1.5 billion for gene therapy firm
The prize novartis has its eyes on is, well, eyes. The Swiss healthcare giant announced Wednesday it's ...
December 22, 2021, 9:00 pm
novartis launches new share buyback of up to $15 billion
novartis AG said on Thursday it was launching a new share buyback of up to $15 billion to be executed b...
December 16, 2021, 1:15 am
novartis launches new share buyback of up to $15 billion
novartis AG said on Thursday it was launching a new share buyback of up to $15 billion to be executed b...
December 16, 2021, 1:15 am
novartis launches new share buyback of up to $15 billion
novartis AG said on Thursday it was launching a new share buyback of up to $15 billion to be executed b...
December 16, 2021, 1:15 am
novartis sees strong interest in sandoz generics unit - finanz und wirtschaft
novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals ...
December 11, 2021, 8:40 am
novartis sees strong interest in sandoz generics unit - finanz und wirtschaft
novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals ...
December 11, 2021, 8:40 am
novartis sees strong interest in sandoz generics unit - finanz und wirtschaft
novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals ...
December 11, 2021, 8:40 am
novartis ceo says sandoz attracting interest - paper
novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buye...
December 10, 2021, 12:02 am
novartis ceo says sandoz attracting interest - paper
novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buye...
December 10, 2021, 12:02 am
novartis ceo says sandoz attracting interest - paper
novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buye...
December 10, 2021, 12:02 am
novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings
novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), ...
December 8, 2021, 1:27 pm
novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings
novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), ...
December 8, 2021, 1:27 pm
novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings
novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), ...
December 8, 2021, 1:27 pm
novartis sees annual sales growth of 4% until 2026
Swiss drugmaker novartis is confident to reach a core margin in innovative medicines in the high 30s by...
December 2, 2021, 1:39 am
novartis sees annual sales growth of 4% until 2026
Swiss drugmaker novartis is confident to reach a core margin in innovative medicines in the high 30s by...
December 2, 2021, 1:39 am
novartis sees annual sales growth of 4% until 2026
Swiss drugmaker novartis is confident to reach a core margin in innovative medicines in the high 30s by...
December 2, 2021, 1:39 am
novartis' iptacopan meets primary endpoint goal in rare kidney disease trial
novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor,...
November 4, 2021, 1:45 pm
novartis' iptacopan meets primary endpoint goal in rare kidney disease trial
novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor,...
November 4, 2021, 1:45 pm
novartis' iptacopan meets primary endpoint goal in rare kidney disease trial
novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor,...
November 4, 2021, 1:45 pm
novartis will sell back its roche stake for $21 billion. both stocks are rising.
A Roche shareholder since 2001, novartis expects to report a gain of $14 billion from the stake sale, w...
November 4, 2021, 5:32 am